IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES
The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
1 . (canceled)
2 . A method for treating primary biliary cirrhosis (PBC) comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, or a pharmaceutically acceptable salt thereof, and ursodeoxycholic acid.
3 . The method of claim 2 , wherein the IBAT inhibitor and the ursodeoxycholic acid are administered simultaneously.
4 . The method of claim 2 , wherein the IBAT inhibitor and the ursodeoxycholic acid are administered separately.
5 . The method of claim 2 , wherein the IBAT inhibitor and the ursodeoxycholic acid are administered sequentially.
6 . The method of claim 2 , wherein treatment of primary biliary cirrhosis comprises treatment of pruritis.
7 . The method of claim 2 , wherein treatment of primary biliary cirrhosis comprises decreasing the level of serum bile acids in the subject.
8 . The method of claim 2 , wherein the IBAT inhibitor is not systemically absorbed.
9 . A method for treating a liver disease selected from the group consisting of primary biliary cirrhosis (PBC); Alagille syndrome (ALGS); primary sclerosing cholangitis (PSC); and progressive familial intrahepatic cholestasis (PFIC), the method comprising orally administering to a subject in need of such treatment a therapeutically effective amount of an IBAT inhibitor, or a pharmaceutically acceptable salt thereof, and ursodeoxycholic acid.
10 . The method of claim 9 , wherein the IBAT inhibitor and the ursodeoxycholic acid are administered simultaneously.
11 . The method of claim 9 , wherein the IBAT inhibitor and the ursodeoxycholic acid are administered separately.
12 . The method of claim 9 , wherein the IBAT inhibitor and the ursodeoxycholic acid are administered sequentially.
13 . The method according to claim 9 , wherein the liver disease is primary biliary cirrhosis (PBC).
14 . The method according to claim 9 , wherein the liver disease is Alagille syndrome (ALGS)
15 . The method according to claim 9 , wherein the liver disease is progressive familial intrahepatic cholestasis (PFIC).
16 . The method of claim 15 , wherein the progressive familial intrahepatic cholestasis is Byler syndrome.
17 . The method of claim 15 , wherein the progressive familial intrahepatic cholestasis is PFIC 1.
18 . The method according to claim 9 , wherein the liver disease is primary sclerosing cholangitis (PSC).
19 . The method of claim 9 , wherein treatment of the liver disease comprises treatment of pruritis.
20 . The method of claim 9 , wherein treatment of the liver disease comprises decreasing the level of serum bile acids in the subject.
21 . The method of claim 9 , wherein the IBAT inhibitor is not systemically absorbed.
22 - 24 . (canceled)